Title IL-17 u ranom invazivnom raku dojke
Title (english) IL-17 in early invasive breast cancer
Author Marina Popović
Mentor Natalija Dedić Plavetić (mentor)
Mentor Ana Kulić (komentor)
Committee member Stjepko Pleština (predsjednik povjerenstva)
Committee member Drago Batinić (član povjerenstva)
Committee member Jasminka Jakić-Razumović (član povjerenstva)
Granter University of Zagreb School of Medicine Zagreb
Defense date and country 2022-09-22, Croatia
Scientific / art field, discipline and subdiscipline BIOMEDICINE AND HEALTHCARE Clinical Medical Sciences Oncology
Universal decimal classification (UDC ) 616 - Pathology. Clinical medicine
Abstract Interleukin 17 (IL-17) je središnji medijator upale s višestrukom ulogom u nastanku,
napredovanju i rezistenciji na terapiju tumora različitih sijela. Pojedine studije govore u prilog
antitumorske aktivnosti IL-17 dok je prema drugima nađeno da povećana izraženost IL-17 u
tumorskom tkivu dojke doprinosi agresivnosti tumora i lošijoj prognozi. Uloga IL-17 dosad je
većinom ispitivana na in vitro staničnim modelima i ljudskim ksenograftima. Nedostatak
podataka o učincima IL-17 in vivo predstavlja nepremostivu prepreku u terapijskom
moduliranju IL-17 posredovanih imunoloških reakcija radi uspješnijeg liječenja bolesnika
oboljelih od raka. U ovom istraživanju analizirana je koncentracija IL-17 u serumu 118 žena
oboljelih od ranog invazivnog raka dojke prije operacije i tijekom adjuvantnog liječenja i
uspoređena s koncentracijom IL-17 u serumu kontrolne skupine zdravih žena. Analizirana je
razina izraženosti IL-17 u različitim komponentama pridruženih intraoperativnih uzoraka
bolesnica uključujući invazivnu i in situ komponentu, peritumorsku stromu i normalno tkivo
dojke. Utvrđena je značajno viša serumska koncentracija IL-17 u serumu žena oboljelih od
ranog raka dojke prije početka liječenja (P<0,001), ali i nakon kirurškog odstranjenja tumora
tijekom adjuvantnog liječenja u odnosu na kontrolnu skupinu (P=0,001) koja nije značajno
korelirala s izražajem IL-17 u tumorskom tkivu. Nađen je statistički značajan pad razine
IL-17 u serumu žena oboljelih od ranog raka dojke tijekom adjuvantnog liječenja nakon
operacije u odnosu na vrijednosti prije operacije (P<0,001). Razina IL-17 u serumu bolesnica
oboljelih od ranog raka dojke značajno je negativno korelirala s izražajem estrogenskih
receptora u tumoru. Rezultati govore u prilog tome da je imunološki odgovor u ranom raku
dojke, među ostalim, posredovan i stanicama koje luče IL-17, osobito u trostruko negativnom
raku dojke. Utvrđeno je da po odstranjenju tumora dolazi do smirivanja upalne reakcije
posredovane IL-17, ali se razina IL-17 nakon odstranjenja tumora tijekom adjuvantnog
liječenja ne vraća na normalne vrijednosti već ostaje povišena u odnosu na vrijednosti u
zdravoj populaciji.
Abstract (english) Interleukin 17 (IL-17) has a key role in inflammatory responses. Increased levels of
IL-17 have been reported in the serum of cancer patients. Some studies suggest antitumor
activity of IL-17 and others speak in favor of its association with poorer prognosis. The lack
of data on IL-17 behavior in vivo precludes the usage of IL-17 antibodies in cancer patients.
This study included 118 patients with early invasive breast cancer. The serum concentration
of IL-17 was measured before surgery and during adjuvant treatment and compared with
healthy controls. The level of IL-17 expression in the corresponding tumor tissue samples was
analyzed. Significantly higher serum concentrations of IL-17 were found in the serum of
women with early breast cancer before treatment and during adjuvant treatment without
correlation to tumor tissue IL-17 expression. There was a significant decrease in serum IL-17
levels in women with early breast cancer after surgery compared to preoperative values.
Serum IL-17 levels were significantly negatively correlated with tumor estrogen receptor
expression. The results suggest that the immune response in early breast cancer is mediated
also by IL-17, particularly in triple-negative breast cancer. IL-17-mediated inflammatory
response subsided after tumor removal, but IL-17 levels remained elevated compared to
healthy controls.
Keywords
Interleukin-17
Receptori
estrogen
Trostruko negativne neoplazme dojke
Prognoza
Imunitet
Keywords (english)
Interleukin-17
Receptors
Estrogen
Triple Negative Breast Neoplasms
Prognosis
Immunity
Language croatian
URN:NBN urn:nbn:hr:105:271798
Project Number: 108-1080058-0046 Title: KARCINOM DOJKE-MOLEKULARNE,GENETSKE I KLINIČKE KARAKTERISTIKE Title: BREAST CANCER-MOLECULAR, GENETIC AND CLINICAL CHARACTERISTICS Leader: Damir Vrbanec Jurisdiction: Croatia Funder: MZOS Funding stream: ZP
Study programme Title: Biomedicine and Health Sciences Study programme type: university Study level: postgraduate Academic / professional title: doktor/doktorica znanosti, područje biomedicine i zdravstvo (doktor/doktorica znanosti, područje biomedicine i zdravstvo)
Type of resource Text
Extent 100 str.
File origin Born digital
Access conditions Open access
Terms of use
Repository Dr Med - University of Zagreb School of Medicine Digital Repository
Created on 2022-10-25 07:00:29